 Best Viewed on IE 7 |
|||
|
In
the Spotlight Revlimid Continuous Therapy Demonstrates Improvement in PFS for Newly Diagnosed MM Patients in a Phase III Trial Celgene announced the data from the planned interim analysis of MM-015 – a Phase III, randomized, double-blind study of continuous Revlimid (lenalidomide) therapy for the treatment of patients with newly diagnosed multiple myeloma (MM) who were ineligible for stem cell transplant – and reported that a clinically significant improvement in progression-free survival (PFS), the primary endpoint of the study, was achieved. |
 |
Addition of Bevacizumab to Conventional Therapy Improved PFS in HER2-positive Breast Cancer Data evaluated by an independent review committee revealed that the addition of bevacizumab to trastuzumab and docetaxel significantly improved PFS in HER2-positive breast cancer, despite findings from an investigator assessment that the improvement was present but statistically non-significant. Results from AVEREL, a randomized, Phase III trial were presented at the 2011 CTRC–AACR San Antonio Breast Cancer Symposium.
|
|
|
........................................................................................................................................................................................................................................
Tumor of the Month - Multiple Myeloma Although multiple myeloma (MM) is the second most common blood cancer, it is relatively rare: the lifetime risk for Americans is only 1:159 (0.63%). The National Cancer Institute has estimated 20,520 new cases for 2011(11,400 men and 9,120 women) with 10,610 deaths in the US. Male gender, obesity, a family history of MM, and exposure to radiation are all risk factors for MM, as well as age >50 years. African Americans are most likely to develop the disease, while Asian Americans are the least likely.
........................................................................................................................................................................................................................................... |
|||
|
The E-newsletter team: Dr. Shirish Kumar, Sarika Manchanda, Dr. Vinamrata Bhatia, Kimberly Tully, Courtenay Veenis, Monica Tuli.
Copyright©2012 SMARTANALYST Inc. All rights reserved CLICK HERE unsubscribe from the list CLICK HERE for previous issues |
|||
 |
|
At SMARTANALYST, we support the decision-making process for licensing, business development, new product planning, and R&D groups within pharmaceutical and biotech companies. We currently work with leading pharmaceutical and biotech firms globally. |
|
